NAGE
Niagen Bioscience, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.99
−0.17%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.99
From 52W high−70.80%
Volume609152.00
Market cap$236.59M
P/E (TTM)15.4x
P/S (TTM)1.8x
Div yield—
Key dataSep 18, 2026
Open
$2.99
From 52W high
−70.80%
Volume
609152.00
Market cap
$236.59M
ValuationView details →
P/E (Fwd)
24.3x
EV/EBITDA
9.3x
P/E (TTM)
15.4x
RSI (14)
42.0
MomentumView details →
1D Return
−0.17%
YTD Return
−52.52%
SummaryUpdated Jun 1, 2026
ChromaDex Corporation (NASDAQ:CDXC) is a bioscience company founded in 1999 and headquartered in Los Angeles, California. The company specializes in healthy aging research and is a leader in the development of nicotinamide adenine dinucleotide (NAD) precursor technologies. ChromaDex went public in 2015 and has evolved from a contract research organization into a consumer health company focused on NAD boosting supplements and potential pharmaceutical applications. The company is known for its proprietary ingredient Niagen and its consumer brand TRU NIAGEN, which targets the growing market of consumers interested in longevity and cellular health optimization.
Similar companies
Latest newsMore news →
Niagen Bioscience's wholly owned subsidiary NAD Pharmaceuticals Corp. engaged life sciences advisory firm Red Sky Partners to support advancement of its investigational drug candidate NB4168.3d agoNiagen Bioscience announced that CEO Rob Fried and CFO Ozan Pamir will participate in Canaccord Genuity's Well Summit in New York from September 28 to 30, 2026.10d ago